-

Genetesis Announces New Scientific Advisory Board

MASON, Ohio--(BUSINESS WIRE)--Genetesis, the market leader in the design, development and commercialization of biomagnetic imaging solutions, today announced its new Scientific Advisory Board (SAB). The group is comprised of world-class experts, researchers and thought leaders spanning cardiology, emergency medicine and radiology. The newly appointed SAB will play a key role in helping to shape the company’s product and commercial roadmap, clinical strategy and R&D activities.

"We are pleased to announce this Scientific Advisory Board, and to be working closely with some of the scientific and clinical luminaries in our field,” said Peeyush Shrivastava, CEO of Genetesis. “The experts joining this team will be instrumental in achieving our clinical and product development plans for CardioFlux, and we appreciate their support of our mission to create a more patient and provider centric standard of care.”

The members of the Genetesis SAB include (alphabetically listed):

Alexander Ding, M.D., M.S., M.B.A., Medical Director in the Office of Health Affairs and Advocacy at Humana, Assistant Professor of Radiology at the University of Louisville, and Chair of the American Medical Association's Council on Science and Public Health. Dr. Alex Ding advises companies in healthcare and medtech innovation, having worked with Doximity, Eko, and Google. He holds a gubernatorial appointment, serving as Trustee of the Health Professions Education Foundation in the California Department of Healthcare Access and Information.

Simon Mahler, M.D., M.S., FACEP, Chief Medical Officer of Impathiq inc, Professor of Emergency Medicine and Director of Clinical Research at Wake Forest School of Medicine. Dr. Simon Mahler developed the HEART Pathway poised to create a more efficient, safe and accurate triage process for patients presenting to the Emergency Department with acute chest pain.

W. Frank Peacock IV, MD, FACEP, FACC, FESC, Professor of Emergency Medicine and Vice Chair for Research in the department of Emergency Medicine at Baylor College of Medicine, in Houston, Texas. With over 600 publications, he is a 3-time winner of the Best Research Paper of the Year Award from the American College of Emergency Physicians, and he was the 2019 recipient of the Ray Bahr Award for Excellence from the American College of Cardiology.

Margarita Pena, M.D., FACEP, Associate Program Director of Emergency Medicine and Medical Director of Clinical Decision Unit at Ascension St. John Hospital and Clinical Professor at Wayne State University College of Medicine. Dr. Margarita Pena served as the PI of the first pilot study of CardioFlux, evaluating emergency department observation unit chest pain patients for Acute Coronary Syndrome.

Viviany Taqueti, M.D., MPH, FACC, Director of the Cardiac Stress Laboratory at Brigham and Women's Hospital and Faculty at Harvard Medical School. Dr. Viviany Taqueti is a physician-scientist with expertise in applying advanced imaging technologies to evaluate cardiovascular outcomes in ischemic and inflammatory heart disease. She is a member of the Faculty Council at Harvard Medical School, associate member at the Broad Institute of MIT and Harvard, and Chair of the Scientific Publications Committee of the American College of Cardiology. She is also an advisor at Broadview Ventures.

To read full bios for each of the SAB Members, click here.

About Genetesis

Genetesis, Inc. is a medical imaging company focused on redefining the way myocardial ischemia and coronary artery disease are detected. By combining CardioFlux, our noninvasive biomagnetic imaging technology, with our proprietary cloud-based web services and machine-learning capabilities, we seek to become the standard of care for diagnosis of cardiovascular disease in the outpatient and acute care settings. Genetesis was founded in 2013 and is based in Mason, Ohio. For more information, visit https://genetesis.com/.

Contacts

Rhea Malhotra, 513-309-1440
Director, Product, rhea@genetesis.com

Genetesis, Inc.


Release Versions

Contacts

Rhea Malhotra, 513-309-1440
Director, Product, rhea@genetesis.com

Social Media Profiles
More News From Genetesis, Inc.

Genetesis Announces Formal Publication of Results from the MAGNETO Trial

MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that official results from its MAGNETO trial were published in a special issue of the American Heart Journal Plus: Cardiology Research and Practice. The results of MAGNETO demonstrate MCG’s ability to identify myocardial ischemia in low-to-intermediate risk patients presenting to the emergency department (ED) with acute chest pain and validate MCG’s performance compared to tests th...

Genetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia Using CardioFlux MCG

MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD). Historically, CMD has been hard to identify in clinical practice due to a lack of effective functional diagnostics with...

Genetesis Announces New Appointments to Executive Leadership Team

MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux. This announcement comes in anticipation of market authorization from the FDA, which Genetesis expects to see later this year. “As we inch ever closer to the FDA granting our De Novo request,...
Back to Newsroom